Skip to content
Cryptos: 561Market Cap: $2.83T 1.6%24h Vol: $152.00BDominance: BTC 58.1% ETH 10.4%
Open Tradzy

New high · Switzerland stocks

Moderna, Inc. (MRNA) closes at a 9-month high of CHF 203.00

Its second new 9-month high in 5 sessions. Up 33.9% over 20 sessions.

Published 21 October 2026 · Written from Tradzy's price and volume data

Close
CHF 203.00
On the day
+5.4%
Volume
no average yet
vs 9-month high
New high

Moderna, Inc. closing prices

CHF 50.00CHF 100.00CHF 150.00CHF 200.00Jun '26Jul '26Aug '26Sep '26Sep '26Oct '26CHF 203.00

The last 90 closes up to 21 October 2026. The live chart is on the MRNA page.

What happened

Moderna, Inc. (MRNA) closed at CHF 203.00 on 21 October 2026, up 5.4% from CHF 192.56 the session before.

It was the third higher close in a row. It is the second new high in the last 5 sessions. Over 5 sessions the price is up 10.6%, and over 20 sessions it is up 33.9%.

That close is above every close of the past 9 months. The previous highest was CHF 198.88 on 15 Oct 2026, and the new close is 2.1% above it.

Across the 8 SWISS stocks we track, 4 closed higher and 4 closed lower that day, with a median change of −0.00%. MRNA's change was +5.4%.

This page reports what the price and volume data show. It does not say why the price moved.

The numbers

Previous closeCHF 192.56
CloseCHF 203.00
Change on the day+5.42%
Change over 5 sessions+10.59%
Change over 20 sessions+33.89%
Volume25.00
Average volume, up to 20 sessions beforenot enough history
Volume against that averagenot enough history
Highest close in the past 9 monthsCHF 198.88 (15 Oct 2026)
Lowest close in the past 9 monthsCHF 24.82 (5 Jan 2026)

The full chart and history are on Moderna, Inc. (MRNA). More from this market: SWISS news today.

More SWISS moves on 21 October 2026

Want a plan for MRNA? Open it in Tradzy: the Analyst Engine reads the chart and lays out an entry, a stop and targets, and you can practise the trade with paper money first.

Open Tradzy

Built from Tradzy's own price and volume data. It reports what the market did and does not say why. Nothing here is financial advice. See the disclaimer.